Browse News
Filter News
Found 30 articles
-
Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member
10/14/2021
Today, Octant announced the appointment of Mark Murcko as Strategic Advisor and Board Member.
-
Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.
-
Dewpoint Therapeutics Appoints Lori Escobedo as Chief People Officer
9/28/2021
Dewpoint Therapeutics, the biomolecular condensates company, today announced the appointment of Lori Escobedo as Chief People Officer.
-
PureTech Health plc – Half-Year Report
8/24/2021
PureTech Health plc announces its half-yearly results for the six months ended June 30, 2021.
-
Dewpoint Appoints Michael Wagner, Ph.D., as Senior Vice President of Chemistry and Drug Discovery
6/16/2021
Dewpoint Therapeutics today announced the appointment of Michael Wagner, Ph.D., as Senior Vice President of Chemistry and Drug Discovery.
-
Blackstone Life Sciences Expands Team of Biopharmaceutical, Medical Technology, and Diagnostics Experts with Appointments of Dr. Olivier Brandicourt, Dr. Omar Ishrak, Dr. Francois Nader, and Kim Popovits as Senior Advisors
5/24/2021
Blackstone Life Sciences, the life sciences business of Blackstone (NYSE:BX), today announced the appointments of Dr. Olivier Brandicourt, former CEO of Sanofi, Dr. Omar Ishrak, former Chairman and CEO of Medtronic, Dr. Francois Nader, former CEO of NPS Pharma, and Kim Popovits, former CEO of Genomic Health, as Senior Advisors.
-
Dewpoint Therapeutics Appoints Isaac Klein, M.D., Ph.D., as Chief Scientific Officer
4/21/2021
Dewpoint Therapeutics , the biomolecular condensates company, today announced the appointment of Isaac Klein, M.D., Ph.D., as Chief Scientific Officer, effective May 3, 2021 .
-
The New York-based company inked a deal with Microsoft to develop unique digital pathology tools for oncology and also announced its seed funding round was extended from $12 million to $44 million.
-
Volastra Therapeutics Extends Seed Financing to $44 Million to Advance Drug Discovery Programs to Prevent Cancer Metastasis
4/6/2021
Company founded by Polaris Partners with latest financing led by Vida Ventures Funding will support advancement of novel approaches to predict and target metastasis, one of the biggest unsolved challenges in cancer
-
Volastra Therapeutics and Dewpoint Therapeutics Partner to Discover Novel Condensate Modulators for Cancer Treatment
3/9/2021
Collaboration will combine Volastra's expertise in cancer biology with Dewpoint's platform for targeting condensates to identify drug candidates that can stop metastasis and disease progression
-
Dewpoint Therapeutics Appoints Regina Barzilay, Ph.D., to its Board of Directors
2/16/2021
Dewpoint Therapeutics , the biomolecular condensates company, today announced that it has appointed Regina Barzilay , Ph.D., to its Board of Directors.
-
Dewpoint Therapeutics Appoints Joel Sendek as Chief Financial Officer
2/11/2021
Dewpoint Therapeutics, the biomolecular condensates company, today announced it has appointed Joel Sendek as Chief Financial Officer and Treasurer.
-
Here’s a run-down of some of the most recent collaboration announcements this week.
-
Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy
1/6/2021
Dewpoint Therapeutics, the biomolecular condensates company, today announced a new research collaboration with Pfizer (NYSE: PFE) for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and one of two types of myotonic dystrophy.
-
BioSpace Movers & Shakers, Dec. 11
12/11/2020
Biopharma and life science companies and organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Cambridge-based Faze Medicines, the biotechnology company that develops therapeutics based on biomolecular condensates, announced today that it has raised $81 million in a Series A round of financing.
-
Dewpoint Appoints Kara Carter, Ph.D., Senior Vice President of Discovery Biology
12/9/2020
Dewpoint Therapeutics, the biomolecular condensates company, today announced it has appointed Kara Carter, Ph.D., as Senior Vice President of Discovery Biology.
-
BioSpace Movers & Shakers, Oct. 16
10/16/2020
Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers. -
Dewpoint Therapeutics Appoints Ameet Nathwani as Chief Executive Officer
10/13/2020
Nathwani joins Dewpoint after serving as Chief Medical Officer, Chief Digital Officer, and Executive Committee member at Sanofi
-
Dewpoint Therapeutics Raises $77M Series B Financing to Advance the Development of Drugs That Target Biomolecular Condensates
9/29/2020
Dewpoint Therapeutics, the biomolecular condensates company, announced it has raised $77 million in a Series B financing.